Related Experiment Video

Updated: Aug 8, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Inhibition of poly(ADP-ribose) polymerase in cancer

Elizabeth Ruth Plummer1

  • 1Northern Institute for Cancer Research, Paul O'Gorman Building, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. e.r.plummer@ncl.ac.uk

Current Opinion in Pharmacology
|June 7, 2006
PubMed

Insights

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are being tested in clinical trials. These inhibitors may enhance chemotherapy or radiation, and show promise as standalone treatments for rare inherited cancers with DNA repair defects.

Area of Science:

  • Biochemistry
  • Oncology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA repair enzyme.
  • PARP-1 inhibition is a strategy for chemo- or radio-potentiation.
  • Emerging evidence suggests PARP inhibitors may be effective as single agents in specific rare inherited cancers with DNA repair defects.

Purpose of the Study:

  • To investigate the potential of PARP-1 inhibitors in cancer treatment.
  • To explore the efficacy of PARP inhibitors as monotherapy in rare inherited cancers.
  • To evaluate the role of PARP-1 inhibition in chemo- or radio-sensitization.

Main Methods:

  • Pre-clinical investigations of PARP-1 inhibition.
  • Clinical trials of potent PARP-1 inhibitors.
  • Analysis of treatment outcomes in patients with rare inherited cancers.

Main Results:

  • PARP-1 inhibition has been extensively studied pre-clinically.
  • Potent PARP-1 inhibitors have entered early clinical trials.
  • PARP inhibitors show potential as single agents in specific cancer types.

Conclusions:

  • PARP-1 inhibitors are a promising area of cancer research.
  • Clinical trials are ongoing to determine the efficacy of PARP inhibitors.
  • Targeting DNA repair pathways offers a novel therapeutic strategy for certain cancers.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...